Who are Eupenta Inj.'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): IPTp-dihydroartemisinin-piperaquine plus metronidazole.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/eupenta-inj.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Eupenta Inj. — Competitive Intelligence Brief

Eupenta Inj. (Eupenta Inj.) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiprotozoal agent. Area: Infectious Disease.

marketed Antiprotozoal agent Parasite DNA and mitochondrial function Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Eupenta Inj. (Eupenta Inj.) — LG Chem. Eupenta is a pentamidine-based antiprotozoal agent that disrupts parasite DNA and mitochondrial function.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Eupenta Inj. TARGET	Eupenta Inj.	LG Chem	marketed	Antiprotozoal agent	Parasite DNA and mitochondrial function
IPTp-dihydroartemisinin-piperaquine plus metronidazole	IPTp-dihydroartemisinin-piperaquine plus metronidazole	London School of Hygiene and Tropical Medicine	phase 3	Antimalarial combination with antibiotic/antiprotozoal agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiprotozoal agent class)

LG Chem · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Eupenta Inj. — Competitive Intelligence Brief. https://druglandscape.com/ci/eupenta-inj. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab